Publications
Found 7 results
Filters: Author is X. Su [Clear All Filters]
“Evaluation of candidate barcoding markers in Orinus (Poaceae)”, vol. 15, p. -, 2016.
, “Evaluation of candidate barcoding markers in Orinus (Poaceae)”, vol. 15, p. -, 2016.
, “Evaluation of candidate barcoding markers in Orinus (Poaceae)”, vol. 15, p. -, 2016.
, “Association between V4 polymorphism in the ADAM33 gene and asthma risk: a meta-analysis”, vol. 14, pp. 989-999, 2015.
, “Association of the CYP1A1 MspI and TNFα-308 polymorphisms with chronic obstructive pulmonary disease in Inner Mongolia”, vol. 13, pp. 3209-3217, 2014.
, “Risk factors for the development of essential hypertension in a Mongolian population of China: a case-control study”, vol. 13, pp. 3283-3291, 2014.
, “Association of the PPARγ2 gene Pro12Ala variant with primary hypertension and metabolic lipid disorders in Han Chinese of Inner Mongolia”, vol. 9, pp. 1312-1320, 2010.
, Ahmed W, Ziouzenkova O, Brown J, Devchand P, et al. (2007). PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J. Intern. Med. 262: 184-198.
http://dx.doi.org/10.1111/j.1365-2796.2007.01825.x
PMid:17645586
Buzzetti R, Petrone A, Caiazzo AM, Alemanno I, et al. (2005). PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity. Pediatr. Res. 57: 138-140.
http://dx.doi.org/10.1203/01.PDR.0000147728.62185.21
PMid:15531738
Douglas JA, Erdos MR, Watanabe RM, Braun A, et al. (2001). The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes 50: 886-890.
http://dx.doi.org/10.2337/diabetes.50.4.886
PMid:11289057
Ereqat S, Nasereddin A, Azmi K, Abdeen Z, et al. (2009). Impact of the Pro12Ala polymorphism of the PPAR-gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients. PPAR Res. 2009: 874126.
http://dx.doi.org/10.1155/2009/874126
PMid:19859551 PMCid:2766506
Gouni-Berthold I, Giannakidou E, Muller-Wieland D, Faust M, et al. (2005). Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. J. Hypertens. 23: 301-308.
http://dx.doi.org/10.1097/00004872-200502000-00012
PMid:15662218
Greene ME, Blumberg B, McBride OW, Yi HF, et al. (1995). Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 4: 281-299.
PMid:7787419
Hasstedt SJ, Ren QF, Teng K and Elbein SC (2001). Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J. Clin. Endocrinol. Metab. 86: 536-541.
http://dx.doi.org/10.1210/jc.86.2.536
PMid:11158005
He W (2009). PPARgamma2 polymorphism and human health. PPAR. Res. 2009: 849538.
http://dx.doi.org/10.1155/2009/849538
PMid:19390629 PMCid:2669649
Horiki M, Ikegami H, Fujisawa T, Kawabata Y, et al. (2004). Association of Pro12Ala polymorphism of PPARgamma gene with insulin resistance and related diseases. Diabetes Res. Clin. Pract. 66 (Suppl 1): S63-S67.
http://dx.doi.org/10.1016/j.diabres.2003.09.023
PMid:15563983
Mirzaei H, Akrami SM, Golmohammadi T, Doosti M, et al. (2009). Polymorphism of Pro12Ala in the peroxisome proliferator-activated receptor gamma2 gene in Iranian diabetic and obese subjects. Metab. Syndr. Relat. Disord. 7: 453-458.
http://dx.doi.org/10.1089/met.2008.0099
PMid:19558269
Ostgren CJ, Lindblad U, Melander O, Melander A, et al. (2003). Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project. J. Hypertens. 21: 1657-1662.
Pinterova D, Cerna M, Kolostova K, Novota P, et al. (2004). The frequency of alleles of the Pro12Ala polymorphism in PPARgamma2 is different between healthy controls and patients with type 2 diabetes. Folia Biol. 50: 153-156.
Rodriguez-Esparragon FJ, Rodriguez-Perez JC, Macias-Reyes A and Alamo-Santana F (2003). Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension. J. Hypertens. 21: 1649-1655.
http://dx.doi.org/10.1097/00004872-200309000-00013
PMid:12923396
Sookoian S, Garcia SI, Porto PI, Dieuzeide G, et al. (2005). Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents. J. Mol. Endocrinol. 35: 373-380.
http://dx.doi.org/10.1677/jme.1.01837
PMid:16216916
Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, et al. (2006). Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes. J. Hum. Hypertens. 20: 684-692.
http://dx.doi.org/10.1038/sj.jhh.1002040
PMid:16625233
Swarbrick MM, Chapman CM, McQuillan BM, Hung J, et al. (2001). A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur. J. Endocrinol. 144: 277-282.
http://dx.doi.org/10.1530/eje.0.1440277
PMid:11248748
Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, et al. (2004). Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J. Lipid Res. 45: 674-685.
http://dx.doi.org/10.1194/jlr.M300363-JLR200
PMid:14729856
Tamori Y, Masugi J, Nishino N and Kasuga M (2002). Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51: 2045-2055.
http://dx.doi.org/10.2337/diabetes.51.7.2045
PMid:12086932
Tavares V, Hirata RD, Rodrigues AC, Monte O, et al. (2005). Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes. Metab. 7: 605-611.
http://dx.doi.org/10.1111/j.1463-1326.2004.00453.x
PMid:16050954
Vanden Heuvel JP (2007). The PPAR resource page. Biochim. Biophys. Acta 1771: 1108-1112.
http://dx.doi.org/10.1016/j.bbalip.2007.03.007
PMid:17493868
Yliharsila H, Eriksson JG, Forsen T, Laakso M, et al. (2004). Interactions between peroxisome proliferator-activated receptor-gamma 2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication. J. Hypertens. 22: 1283-1287.
http://dx.doi.org/10.1097/01.hjh.0000125438.28861.a4
PMid:15201543
Zietz B, Barth N, Spiegel D, Schmitz G, et al. (2002). Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male Caucasian type 2 diabetes patients. Exp. Clin. Endocrinol. Diabetes 110: 60-66.
http://dx.doi.org/10.1055/s-2002-23487
PMid:11928067